Last checked at 29 Sep 2020 15:51
Director Dealings
Oxford, UK - 29 September 2020: Oxford Biomedica plc ("Oxford Biomedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, today announces that Vulpes Life Sciences Fund ("Vulpes"), whose portfolio manager Martin Diggle is a Non-Executive Director on the Board of Oxford Biomedica, has entered into a pledge of security of 750,000 ordinary shares ("Transferred Shares") in connection with a financing transaction in the normal course of business for Vulpes.
Vulpes is required to redeem the Transferred Shares at maturity when the loan is repaid at the end of the three year term.
Following this transaction Vulpes Testudo/Vulpes Life Sciences Fund holds 10,713,616 ordinary shares representing 13.0% of the Company.
The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the transaction in number of Ordinary Shares.
1. | Details of the person discharging material responsibilities/person closely associated
| ||
a. | Name | Vulpes Life Sciences Fund | |
2. | Reason for the notification
| ||
a. | Position/status | Martin Diggle, Non-Executive Director
| |
b. | Initial notification /amendment | Initial notification
| |
3. | Details of the issuer, emission allowance, market participant, auction platform, auctioneer or auction monitor
| ||
a. | Name | Oxford Biomedica plc
| |
b. | Legal Entity Identifier | 213800S1GVQNXQ15K851
| |
4. | Details of the transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||
a. | Description of the financial instrument, type of instrument identification code | Oxford Biomedica plc Ordinary Shares of 50p each
GB00BDFBVT43
| |
b. | Nature of the transaction | Pledge of ordinary shares as a security in relation to a corporate loan
| |
c. | Currency | GBP - British Pound
| |
d. | Price(s) and volume(s) |
Price(s)
|
Volume(s) |
NA
| 750,000
| ||
|
| ||
e. | Aggregated information · Aggregated volume · Price · Aggregated total
|
750,000
NA NA
| |
f. | Date of the transaction | 2020-09-25
| |
g. | Place of the transaction | Outside of a trading venue
| |
The issued share capital of the Group is 82,223,225 ordinary 50p shares.
-Ends-
For further information, please contact: |
|
Oxford Biomedica plc: Natalie Walter, Company Secretary |
Tel: +44 (0)1865 783 000 |
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Santen, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally the group has signed a Clinical and Commercial Supply Agreement with AstraZeneca for manufacture of the adeno based COVID-19 vaccine candidate, AZN1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 580 people. Further information is available at www.oxb.com.